NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

復發性多形性膠質母細胞瘤治療藥的全球市場和新型冠狀病毒感染疾病 (COVID-19)的影響分析:各治療法、各終端用戶、各地區 - 市場規模,佔有率,預測 (2021年∼2027年)

Recurrent Glioblastoma Multiforme Treatment Market with COVID-19 Impact Analysis, By Treatment, By End User, and By Region - Size, Share, & Forecast from 2021-2027

出版商 AnalystView Market Insights 商品編碼 980663
出版日期 內容資訊 英文 210 Pages
商品交期: 2-3個工作天內
價格
復發性多形性膠質母細胞瘤治療藥的全球市場和新型冠狀病毒感染疾病 (COVID-19)的影響分析:各治療法、各終端用戶、各地區 - 市場規模,佔有率,預測 (2021年∼2027年) Recurrent Glioblastoma Multiforme Treatment Market with COVID-19 Impact Analysis, By Treatment, By End User, and By Region - Size, Share, & Forecast from 2021-2027
出版日期: 2020年12月01日內容資訊: 英文 210 Pages
簡介

全球復發性多形性膠質母細胞瘤治療藥的市場規模,預計2020年達到4億3080萬美元,2021年∼2027年以6.8%的年複合成長率成長。市場主要促進因素,是飲酒數量增加和生活習慣的變化,發作的發病率上升等。各地區中北美各國成為最大的市場。

本報告提供全球復發性多形性膠質母細胞瘤的治療藥的市場相關分析,市場定義和基本結構,主要的推動及阻礙市場要素,產業的競爭力、向心力,市場佔有率結構,各治療法、各終端用戶、各地區的市場趨勢預測 (過去5年、今後7年份),主要企業的簡介,新型冠狀病毒感染疾病 (COVID-19)的影響等調查。

目錄

第1章 復發性多形性膠質母細胞瘤治療藥:市場概要

第2章 摘要整理

第3章 復發性多形性膠質母細胞瘤治療藥市場:主要的市場趨勢

  • 推動市場要素
    • 推動市場要素的影響度分析
  • 阻礙市場要素
    • 阻礙市場要素的影響度分析
  • 市場機會
  • 未來市場趨勢

第4章 復發性多形性膠質母細胞瘤治療藥市場:產業研究

  • 波特的五力分析
  • 行銷策略分析
  • 市場成長預測:製圖
  • 管理體制分析

第5章 復發性多形性膠質母細胞瘤治療藥市場:新型冠狀病毒感染疾病 (COVID-19)的影響分析

  • "COVID-19前" 的影響分析
  • "COVID-19後" 的影響分析
    • 高業績市場區隔
    • 邊際成長市場區隔
    • 低業績市場區隔
    • 邊際損失市場區隔

第6章 復發性多形性膠質母細胞瘤治療藥市場:市場環境

  • 市場佔有率分析 (2019年)
  • 主要的技術創新企業的分析
  • 市場區隔資料:各主要製造商
    • 現有企業分析
    • 新企業分析

第7章 復發性多形性膠質母細胞瘤治療藥市場:各治療法

  • 概要
  • 放射線敏化劑
  • 口服藥
  • 亞硝脲類藥物
  • 化療
  • 放射治療

第8章 復發性多形性膠質母細胞瘤治療藥市場:各終端用戶

  • 概要
  • 醫院、診所
  • 門診病人手術中心
  • 其他

第9章 復發性多形性膠質母細胞瘤治療藥市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區(APAC)
  • 南美
  • 中東、非洲

第10章 供應商分析

  • 競爭儀表板
  • 企業簡介
    • Pfizer, Inc.
    • GlaxoSmithKline plc.
    • AstraZeneca
    • F. Hoffman-La Roche, Ltd.
    • Merck & Co., Inc.
    • Vascular Biogeneics
    • AngioChem, Inc.
    • Boehringer Ingelheim GmbH
    • Celldex Therapeutics, Inc.
    • Cavion LLC
    • Bristol-Myers Squibb Company
    • Boston Biomedical, Inc.
    • Cantex Pharmaceuticals, Inc.
    • Coherus BioSciences, Inc.
    • Cortice Biosciences, Inc.
    • EnGeneIC Ltd.
    • GenSpera, Inc.

第11章 分析師的全方位的分析

第12章 附錄

目錄

REPORT HIGHLIGHT

The global Recurrent Glioblastoma Multiforme Treatment market was valued at USD 430.8 million in 2020, growing with 6.8% CAGR during the forecast period, 2021-2027.

Glioblastoma multiforme (GBMs) is a very common & assertive malignant brain tumor that occurs in humans that includes glial cells. GBM is mainly present in two variants namely, gliosarcoma, and giant cell glioblastoma. Seizure, nausea, hemiparesis, headache, and memory loss are some of the ordinary symptoms witnessed in the patients suffering from glioblastoma. Glioblastoma is mainly occurred in male having age of 65 years & above.

The recurrent glioblastoma multiforme treatment market is anticipated to grow at significant rate owing to increasing occurrence of brain tumor. According to National Foundation of Cancer Research, Glioblastoma is the extreme kind of brain cancers, that constitute for 45.0% of all malignant type brain tumors. Further, according to study by National Brain Tumors Society, more than 10% population with brain tumors are at greater risk of glioblastomas. Treatment for recurrent glioblastoma's multiforme and other type of cancers are enormously affected due to the COVID-19 outbreak. The patients are not able to gain access to health & surgery centers for the treatment of chemotherapy, health monitoring, and radiotherapy. The pandemic has also adversely affected the pharmaceutical & medical supply chain, which is restraining the market growth.

The growing habits of liquor consumption, shifting lifestyle and growing incidence of seizure are the key factors responsible for the growth of market. Glioblastoma is usually treated by surgical treatment by removing the tumor, with the help of chemotherapy treatment and radiation. In addition, new drug approvals, and launches for GBM treatment are expected to boost the market growth. In 2020, Pfizer has launched 'Zirabev' in the U.S. market, which is a kind of biosimilar called Avastin. This drug has been authorized for the treatment of recurrent glioblastoma multiforme's. The biosimilar is also granted by FDA in 2019 for the treatment of metastatic NSCLC, recurrent glioblastoma's, persistent or metastatic colorectal cancer, metastatic cervical cancer, and metastatic renal-cell carcinoma.

North America contributed for largest market share in the overall market. This is contributed by the presence of major market players, increasing healthcare awareness, and FDA approvals for new drugs in the market. For instance, in 2019, Denovo Biopharma, a San Diego-based biotech company, was granted the U.S. Food & Drug Administration (FDA) approval for its phase 2b clinical trial to diagnose GBM patients. The rising focus on research & development and collaboration strategies by key companies in the North America market is also boosting the market growth. Asia Pacific is projected to expand at a significant rate over the forecast period.

The recurrent glioblastoma multiforme treatment market is highly competitive in nature with key players dominating the global market with larger share. Key players focus on strategic collaboration, joint venture to expand their business across the globe. For example, in 2017, DelMar Pharmaceuticals have collaborated with PRA Health Science to perform phase 3 trials of VAL-083 especially treating recurrent GBM.

Key features of the study:

This proposed research study on Recurrent Glioblastoma Multiforme Treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2020-2027), considering 2019 as the base year

The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Recurrent Glioblastoma Multiforme Treatment market

The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Recurrent Glioblastoma Multiforme Treatment market

Impact of COVID-19 on Recurrent Glioblastoma Multiforme Treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Recurrent Glioblastoma Multiforme Treatment market post-COVID will also be covered.

In order to give the users of this report a comprehensive view on the Recurrent Glioblastoma Multiforme Treatment market, we have also included competitive landscape and key innovator analysis for the Recurrent Glioblastoma Multiforme Treatment market.

The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and end-user's attractiveness.

The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Recurrent Glioblastoma Multiforme Treatment market.

In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new product launch, research & development, regional expansion of major participants involved in the Recurrent Glioblastoma Multiforme Treatment market on global as well as regional level.

The global Recurrent Glioblastoma Multiforme Treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET KEY PLAYERS

Pfizer, Inc.

GlaxoSmithKline plc.

AstraZeneca

F. Hoffman-La Roche, Ltd.

Merck & Co., Inc.

Vascular Biogeneics

AngioChem, Inc.

Boehringer Ingelheim GmbH

Celldex Therapeutics, Inc.

Cavion LLC

Bristol-Myers Squibb Company

Boston Biomedical, Inc.

Cantex Pharmaceuticals, Inc.

Coherus BioSciences, Inc.

Cortice Biosciences, Inc.

EnGeneIC Ltd.

GenSpera, Inc.

GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT

Radiosensitizers

Oral Medications

Nitrosoureas Drugs

Chemotherapy

Radiation Therapy

GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER

Hospitals & Clinics

Ambulatory Surgical Centers

Others

GLOBAL RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

The Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

TABLE OF CONTENT

1. Recurrent Glioblastoma Multiforme Treatment Market Overview

  • 1.1. Study Scope

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Treatment
    • 2.1.2. Market Snippet by End User
    • 2.1.3. Market Snippet by Region
  • 2.2. Competitive Insights

3. Recurrent Glioblastoma Multiforme Treatment Key Market Trends

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. Recurrent Glioblastoma Multiforme Treatment Industry Study

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Recurrent Glioblastoma Multiforme Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Recurrent Glioblastoma Multiforme Treatment Market Landscape

  • 6.1. Market Share Analysis, 2019
  • 6.2. Key Innovators Analysis
  • 6.3. Breakdown Data, by Key Manufacturer
    • 6.3.1. Established Players' Analysis
    • 6.3.2. Emerging Players' Analysis

7. Recurrent Glioblastoma Multiforme Treatment Market - By Treatment

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment, 2020 & 2027 (%)
  • 7.2. Radiosensitizers
  • 7.3. Oral Medications
  • 7.4. Nitrosoureas Drugs
  • 7.5. Chemotherapy
  • 7.6. Radiation Therapy

8. Recurrent Glioblastoma Multiforme Treatment Market - By End User

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By End User, 2020 & 2027 (%)
  • 8.2. Hospitals & Clinics
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Others

9. Recurrent Glioblastoma Multiforme Treatment Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2020 & 2027 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By End User, 2016 - 2027, (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.3.10. Rest of Europe
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.3.10.3. Rest of the Europe Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.3.10.4. Rest of the Europe Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.4.10. Rest of APAC
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.4.10.3. Rest of APAC Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.4.10.4. Rest of APAC Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.5.9. Rest of LATAM
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.5.9.3. Rest of LATAM Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.5.9.4. Rest of LATAM Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 - 2027 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By End User, 2016 - 2027 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 - 2027, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Treatment, 2016 - 2027 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Application, 2016 - 2027 (US$ Million)

10. Key Vendor Analysis

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Pfizer, Inc.
    • 10.2.2. GlaxoSmithKline plc.
    • 10.2.3. AstraZeneca
    • 10.2.4. F. Hoffman-La Roche, Ltd.
    • 10.2.5. Merck & Co., Inc.
    • 10.2.6. Vascular Biogeneics
    • 10.2.7. AngioChem, Inc.
    • 10.2.8. Boehringer Ingelheim GmbH
    • 10.2.9. Celldex Therapeutics, Inc.
    • 10.2.10. Cavion LLC
    • 10.2.11. Bristol-Myers Squibb Company
    • 10.2.12. Boston Biomedical, Inc.
    • 10.2.13. Cantex Pharmaceuticals, Inc.
    • 10.2.14. Coherus BioSciences, Inc.
    • 10.2.15. Cortice Biosciences, Inc.
    • 10.2.16. EnGeneIC Ltd.
    • 10.2.17. GenSpera, Inc.

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Recurrent Glioblastoma Multiforme Treatment market: Treatments Snapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by Treatments
  • TABLE Global Recurrent Glioblastoma Multiforme Treatment market, by Treatments 2016-2027 (USD Million)
  • TABLE Recurrent Glioblastoma Multiforme Treatment market: Application Snapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Recurrent Glioblastoma Multiforme Treatment market, by Application 2016-2027 (USD Million)
  • TABLE Recurrent Glioblastoma Multiforme Treatment market: Regional snapshot (2019)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Recurrent Glioblastoma Multiforme Treatment market, by Region 2016-2027 (USD Million)
  • TABLE North America Recurrent Glioblastoma Multiforme Treatment market, by Country, 2016-2027 (USD Million)
  • TABLE North America Recurrent Glioblastoma Multiforme Treatment market, by Treatments, 2016-2027 (USD Million)
  • TABLE North America Recurrent Glioblastoma Multiforme Treatment market, by Application, 2016-2027 (USD Million)
  • TABLE Europe Recurrent Glioblastoma Multiforme Treatment market, by Country, 2016-2027 (USD Million)
  • TABLE Europe Recurrent Glioblastoma Multiforme Treatment market, by Treatments, 2016-2027 (USD Million)
  • TABLE Europe Recurrent Glioblastoma Multiforme Treatment market, by Application, 2016-2027 (USD Million)
  • TABLE Asia Pacific Recurrent Glioblastoma Multiforme Treatment market, by Country, 2016-2027 (USD Million)
  • TABLE Asia Pacific Recurrent Glioblastoma Multiforme Treatment market, by Treatments, 2016-2027 (USD Million)
  • TABLE Asia Pacific Recurrent Glioblastoma Multiforme Treatment market, by Application, 2016-2027 (USD Million)
  • TABLE Latin America Recurrent Glioblastoma Multiforme Treatment market, by Country, 2016-2027 (USD Million)
  • TABLE Latin America Recurrent Glioblastoma Multiforme Treatment market, by Treatment, 2016-2027 (USD Million)
  • TABLE Latin America Recurrent Glioblastoma Multiforme Treatment market, by Application, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Recurrent Glioblastoma Multiforme Treatment market, by Country, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Recurrent Glioblastoma Multiforme Treatment market, by Treatment, 2016-2027 (USD Million)
  • TABLE Middle East and Africa Recurrent Glioblastoma Multiforme Treatment market, by Application, 2016-2027 (USD Million)

List of Figures

  • FIGURE Recurrent Glioblastoma Multiforme Treatment market segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2019
  • FIGURE Treatment segment market share analysis, 2020 & 2027
  • FIGURE Treatment segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Application segment market share analysis, 2020 & 2027
  • FIGURE Application segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Regional segment market share analysis, 2020 & 2027
  • FIGURE Regional segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE North America Recurrent Glioblastoma Multiforme Treatment market share and leading players, 2019
  • FIGURE Europe Recurrent Glioblastoma Multiforme Treatment market share and leading players, 2019
  • FIGURE Asia Pacific Recurrent Glioblastoma Multiforme Treatment market share and leading players, 2019
  • FIGURE Latin America Recurrent Glioblastoma Multiforme Treatment market share and leading players, 2019
  • FIGURE Middle East and Africa Recurrent Glioblastoma Multiforme Treatment market share and leading players, 2019
  • FIGURE North America market share analysis by country, 2019
  • FIGURE U.S. Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Canada Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Europe Recurrent Glioblastoma Multiforme Treatment market share analysis by country, 2019
  • FIGURE Germany Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Spain Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Italy Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE UK Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE France Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of the Europe Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Asia Pacific Recurrent Glioblastoma Multiforme Treatment market share analysis by country, 2019
  • FIGURE India Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE China Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Japan Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE South Korea Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Singapore Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of APAC Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Latin America Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Latin America Recurrent Glioblastoma Multiforme Treatment market share analysis by country, 2019
  • FIGURE Brazil Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Mexico Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Argentina Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Rest of LATAM Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Middle East and Africa Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE Middle East and Africa Recurrent Glioblastoma Multiforme Treatment market share analysis by country, 2019
  • FIGURE Saudi Arabia Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)
  • FIGURE United Arab Emirates Recurrent Glioblastoma Multiforme Treatment market size, forecast and trend analysis, 2016 to 2027 (USD Million)